Column 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
---|---|---|---|---|---|---|---|
Risk score | Cutoffb | Seroconversion visits among visits with a score of at least the cutoffc | Seroconversion visits among visits with a score below the cutoffc | Sensitivity % (95% CI) | Specificity % (95% CI) | Overall AUC (95% CI) | % to be tested |
Development of a risk score in Amsterdam Cohort Studies | |||||||
 A. Initial risk scored,e   -CLAI a conditionf | 2 | 80/1888 | 95/15555 | 45.7 (38.2–53.4) | 89.5 (89.1–90.0) | 0.70 (0.66–0.74) | 10.8 |
 B. 14 symptoms scored as beta coefficient in symptom based modeld,g   -CLAI a conditionf | 0.1 | 90/2342 | 85/15101 | 51.4 (43.8–59.0) | 87.0 (86.4–87.5) | 0.71 (0.67–0.74) | 13.4 |
 C. 14 symptoms scored as beta coefficient in symptom based modelg,h   -CLAI not a condition | 0.2 | 116/4430 | 59/13012 | 66.3 (58.8–73.2) | 75.0 (74.4–75.7) | 0.74 (0.70–0.78) | 25.4 |
 D. 14 symptoms and 3 risk factors, scored as beta coefficient in combined modeli,j | 1.3 | 111/4334 | 24/10858 | 82.2 (74.7–88.3) | 72.0 (71.2–72.7) | 0.83 (0.80–0.87) | 28.5 |
 E. 4 symptoms and 3 risk factors scored as beta coefficient in combined modelk,j | 1.5 | 103/3675 | 32/11517 | 76.3 (68.2–83.2) | 76.3 (75.6–77.0) | 0.82 (0.79–0.86) | 24.2 |
Validation of optimal risk score in Multicenter AIDS Cohort Study | |||||||
 E. 4 symptoms and 3 risk factorsk, scored as beta coefficient | 1.5 | 77/3779 | 60/29274 | 56.2 (47.5–64.7) | 88.8 (88.4–89.1) | 0.78 (0.74–0.82) | 11.4 |